One of MedImmune's shareholders is urging the company to put itself up for sale to a large pharma company. David Katz of Matrix Asset Advisors told the board at MedImmune that a big pharma outfit would be willing to pay as much or more than the company is currently worth if it cashes in on today's hot market for mergers and acquisitions. Analysts noted that Pfizer in particular has been bulling its way into the vaccine market, recently buying the U.K.'s PowderMed. The board at MedImmune, though, swiftly rejected the sales advice, saying that its leaders continue to believe that they can gain the best value for shareholders by staying independent.
- read this report on MedImune from the Washington Business Journal